Tag: Biotechnology Research

Variational AI
Global

Variational AI Announces Generative AI Project With Merck

Merck to evaluate Variational AI’s Enki™ generative AI platform to design novel and selective small molecules VANCOUVER, British Columbia–(BUSINESS WIRE)–Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program. “CQDM is pleased to have facilitated the establishment of collaborations for Variational AI by creating beneficial links … Continue reading Variational AI Announces Generative AI Project With Merck

Impact Newswire
Osivax
Europe, Global

Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer. She brings over 25 years of experience in vaccine development with considerable expertise in influenza vaccines, from early-stage clinical development to approval and post-marketing commitments. Dr. Groth joins … Continue reading Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

Impact Newswire
Aiolos Bio
Global, United States

GSK Enters Agreement to Acquire Aiolos Bio

January 09, 2024 05:52 AM Eastern Standard Time SAN FRANCISCO & LONDON–(BUSINESS WIRE)–GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 … Continue reading GSK Enters Agreement to Acquire Aiolos Bio

Impact Newswire
AdvanCell
Australia, Global

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

SYDNEY–(BUSINESS WIRE)–AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of Anna Karmann, MD, PhD as the company’s Chief Medical Officer based in San Francisco. “Anna’s passion, insights, entrepreneurial mindset and expertise are invaluable to AdvanCell as we develop our portfolio of Targeted Alpha Therapies for patients globally.”Post this Dr. Karmann joins from RayzeBio, … Continue reading AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

Impact Newswire